PARP1 promoter links cell cycle progression with adaptation to oxidative environment by Pietrzak, Julita et al.
Contents lists available at ScienceDirect
Redox Biology
journal homepage: www.elsevier.com/locate/redox
Review article
PARP1 promoter links cell cycle progression with adaptation to oxidative
environment
Julita Pietrzaka, Corinne M. Spickettb, Tomasz Płoszajc, László Virágd,e,
Agnieszka Robaszkiewicza,⁎
a Department of General Biophysics, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland
b School of Life & Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
c Department of Molecular Biology, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland
d Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
eMTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary
A R T I C L E I N F O
Keywords:
Cell proliferation
Redox homeostasis
Poly-ADP-ribose polymerase 1 (PARP1)
Gene transcription
Signaling
DNA repair
A B S T R A C T
Although electrophiles are considered as detrimental to cells, accumulating recent evidence indicates that
proliferating non-cancerous and particularly cancerous cells utilize these agents for pro-survival and cell cycle
promoting signaling. Hence, the redox shift to mild oxidant release must be balanced by multiple defense me-
chanisms. Our latest ﬁndings demonstrate that cell cycle progression, which dictates oxidant level in stress-free
conditions, determines PARP1 transcription. Growth modulating factors regulate CDK4/6-RBs-E2Fs axis. In cells
arrested in G1 and G0, RB1-E2F1 and RBL2-E2F4 dimers recruit chromatin remodelers such as HDAC1, SWI/SNF
and PRC2 to condense chromatin and turn oﬀ transcription. Release of retinoblastoma-based repressive com-
plexes from E2F-dependent gene promoters in response to cell transition to S phase enables transcription of
PARP1. This enzyme contributes to repair of oxidative DNA damage by supporting several strand break repair
pathways and nucleotide or base excision repair pathways, as well as acting as a co-activator of transcription
factors such as NRF2 and HIF1a, which control expression of antioxidant enzymes involved in removal of
electrophiles and secondary metabolites. Furthermore, PARP1 is indispensible for transcription of the pro-sur-
vival kinases MAP2K6, ERK1/2 and AKT1, and for maintaining MAPK activity by suppressing transcription of
the MAPK inhibitor, MPK1. In summary, cell cycle controlled PARP1 transcription helps cells to adapt to a pro-
oxidant redox shift.
1. Pro-oxidant physiology of proliferating cells
Human cells proliferate in a variety of contexts. Controlled cell di-
visions play a particular function for development of the embryo, while
in the adult organism mainly stem and some immune cells retain the
ability to proliferate. Cancer cells, as a special type of transformed cells,
are capable of unlimited and uncontrolled growth. Regardless of the
type of dividing cell, proliferation imposes a requirement for energy
and reducing power. Although mitochondrial oxidative phosphoryla-
tion is the most eﬃcient source of ATP, it can cause extensive release of
O2•-, which is dismutated to H2O2 either in mitochondria (by SOD2) or
in the cytoplasm (by SOD1). Therefore, above some critical threshold
value of this oxidant in cell compartments, aerobic glycolysis becomes
more favorable than oxidative phosphorylation in order to limit the
hazardous waste products resulting from the mitochondrial metabolic
pathway [1]. During fatty acid oxidation, O2•- and H2O2 can also be
produced by xanthine oxidase in peroxisomes, which duplicate and are
segregated between progeny cells. Although metabolically unrelated,
NADPH oxidases act as a primary source of oxidants in macrophages
and some cancer cells [2].
Depending on the cell type, proliferation-inducing agents such as
growth factors (platelet-derived, ﬁbroblast, epidermal, insulin-like and
transforming growth factor β), cytokines (type I interferons, granulo-
cyte-macrophage colony-stimulating factor), mutant K-ras or small
GTPase Rac-1 elevate intracellular O2•- through NADPH oxidase and/or
mitochondria [3,4]. Due to pressure induced by an elevated and sus-
tained redox shift to a mild oxidative environment, cells have devel-
oped eﬃcient mechanisms of adaptation and functional transformation
of „bad” to „good” molecules, which promote cell proliferation and
survival at diﬀerent signaling levels [5].
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2. Cell cycle progression regulates PARP1 transcription
Poly-ADP-ribose polymerase 1 (PARP1) is a multitasking enzyme
that regulates many intracellular processes, including DNA repair,
metabolism, signaling and transcription, by direct interaction with
other proteins and DNA, involving their ADP-ribosylation and auto-
ADP-ribosylation of PARP1. The data acquired and published in the
EMBL-EBI Expression Atlas indicate high PARP1 abundance in pro-
liferating cancerous and non-cancerous cells (e.g. macrophages) [6]. In
search for the link between PARP1 transcription and cell cycle pro-
gression, we recently revealed that cell arrest in G1 or exit to G0 lead to
PARP1 repression by retinoblastoma-based multiprotein complexes,
which are also known to repress transcription of E2F-dependent genes
encoding proteins responsible for cell transition to S phase [7]. The
mode of growth inhibition determines the composition of the repressive
complex at the PARP1 promoter, giving priority to E2F1-RB1 dimers
under G1 arrest in cancer, as well as in CD34+ hematopoietic pro-
genitor/stem cells treated with cyclin-dependent kinases 4 and 6
(CDK4/6) pharmacological inhibitors or depleted of nucleotides by
mimosine. E2F4-RBL2-based complexes were found to be prevalent in
diﬀerentiated cells (Fig. 1). Since PARP1 is involved in cell protection
against oxidants, one may think that PARP1 repression in response to
proliferation arrest may sensitize cells to agents that challenge redox
homeostasis. Some ongoing and recruiting clinical trials have been
testing FDA approved CDK4/6 inhibitors Palbociclib (IBRANCE®,
PD0332991) and Ribociclib (LEE011, Kisqali) in combination with
drugs such as doxorubicin, carboplatin and paclitaxel, which trigger
acute redox imbalance [8].
Furthermore, PARP1 enhances cell proliferation. Hormone-acti-
vated cyclin-dependent kinase 2 (CDK2) phosphorylates and activates
PARP1, thereby facilitating H1 displacement and transcription of the
majority of hormone-responsive genes in breast cancer [9]. In urinary
bladder carcinoma cells, PARP1 regulates cyclin E expression, cell cycle
re-entry and G1/S progression [10]. Thus, high levels of PARP1 in
cancer cells promote cell cycle progression, which is associated with an
increased level of oxidants, thereby maintaining PARP1 transcription
and creating a self-promoting cycle.
3. PARP1 co-activates expression of proteins that enzymatically
decompose oxidants and remove secondary metabolites
The primary role in antioxidant defense and in cell adaptation to
excessive oxidant or electrophile production is fulﬁlled by enzymatic
antioxidant defense, which comprises direct scavengers of electro-
philes, but also enzymes that detoxify the secondary metabolites. Many
such enzymes are under transcriptional control of nuclear factor ery-
throid 2 (NFE2)-related factor 2 (NRF2), a basic leucine zipper (bZIP)
protein, which dissociates from its repressor Keap1 and translocates to
nucleus in response to a physiological shift in redox homeostasis to-
wards oxidant production. NRF2 requires PARP1 for full transcriptional
activity, because PARP1 facilitates interaction of NRF2 and NRF2-
partner (small MAF protein; MAFG) with the antioxidant response
element (ARE) (Fig. 2) [11]. An inhibitory eﬀect of PARP1 knockdowns
was found in breast cancer cells and proliferating mouse ﬁbroblasts.
Although in normal cells NRF2 suppresses tumor promotion and pro-
gression, this pathway is constitutively activated in various cancers by
mutation and transcriptional repression of Keap-1, accumulation of
Keap-1-NRF2 disruptors, transcriptional and post-translational NRF2
induction. In view of NRF2 targets, this transcription factor provides
chemoresistance and, like PARP1, has become a target for anticancer
interventions [12].
Another oxidant-counteracting mechanism that involves PARP1 is
represented by its interaction with the transcription factor hypoxia-in-
ducible factor 1-alpha (HIF1α), which undergoes activation during
hypoxia and hypoxia-triggered redox imbalance [13,14]. PARP1 co-
activates HIF1α-dependent transcription of genes, which promotes cell
survival. In murine embryonic ﬁbroblasts, PARP1 caused accumulation
of HIF1α via upregulation of NO and oxidant production in cells treated
with deferoxamine [15]. In addition to PARP1, HIF1α binds EP300/
CBP acetylase(s) for full transcriptional activity. A similar observation
was made for nuclear factor kappa B (NF-κB), activation of which re-
quired synergistic interaction with PARP1 and EP300/CBP. However,
for HIF1α mutual dependence between these two types of co-activators
has not been documented yet.
Promoters of some antioxidant enzymes such as catalase, SOD1 or
SOD2 carry the binding motif for NF-κB, but the role of PARP1 in
transcription activation of these genes has not been conﬁrmed. Instead,
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Fig. 1. Cell cycle progression dictates PARP1 tran-
scription via growth factors/inhibitors-G1/G0-CDK4/
6-RBs axis. Cell cycle machinery is controlled by external
signals in order to adapt cells to environmental require-
ments and conditions. Stimulation of receptor tyrosine
kinases (RTKs), MYC protooncogene or estrogen receptor
(ER) in response to peptide and non-peptide growth-pro-
moting agents activates cyclin-dependent kinase 4 and 6
(CDK4/6), which associate with cyclin D1 and phosphor-
ylate retinoblastoma proteins (RB1, RBL2). This mod-
iﬁcation keeps retinoblastoma proteins released from
promoters of PARP1 and cell cycle promoting genes,
thereby allowing active gene transcription and enabling
cell transition from G1 to S phase. Upon cell growth arrest
in G1 or cell cycle exit to G0, CDK4/6 inhibition results in
hypophosphorylation of retinoblastoma proteins, their
binding to E2F-driven gene promoters and recruitment of
chromatin remodelers, which are capable of inactivating
gene expression by removing transcription-promoting in-
dicators and/or inserting transcription-inhibiting histone
modiﬁcation(s). It leads to an increase in nucleosome
density and chromatin condensation. Notably, composition
of the repressive complex varies between cells arrested in
G1 and in G0. Limiting PARP1 expression in G0 is achieved
solely by histone deacetylase 1 (HDAC1) for histone dea-
cetylation, while in G1 HDAC1 additionally requires PRC2
(polycomb repressor complex 2) activity and trimethylation of H3K27 by enhancer of zeste homolog 2 (EZH2) to repress PARP1 transcription. Cell cycle arrest in G2
does not aﬀect the mRNA and protein levels of PARP1.
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Fig. 2. PARP1 contributes to antioxidant cell defense by
enhancing transcription of enzymatic scavengers of elec-
trophiles and secondary metabolites. Under normal oxygen
conditions, PARP1 determines intracellular redox home-
ostasis by intensifying nuclear factor erythroid 2 (NFE2)-
related factor 2 (NRF2)-dependent transcription of enzy-
matic redox-balancing enzymes (NAD(P)H quinone oxi-
doreductase 1, NQO1; heme oxygenase-1, HO-1; aldo-keto
reductase family 1, member C1, AKR1C1; superoxide dis-
mutase 1, SOD1), as well as phase II detoxifying enzymes
(glutathione S-transferase, GST; UDP-glucuronosyl-
transferase, UGT; catalytic and modiﬁer subunits of glu-
tamate cysteine ligase, GCLC and GCLM respectively) and
drug transporters (multidrug resistance-associated pro-
teins, MRPs). In the absence of PARP1, transcription of the
above-mentioned genes is restricted as NRF2 moderately
associates with small MAF proteins (in this case with
MAFG) and the antioxidant response element (ARE),
which is localized within the promoter of NRF2 target
genes. When abundant, PARP1 enhances the interaction
among NRF2, MAFG and ARE, thereby acting as a co-ac-
tivator of NRF2-dependent gene transcription. PARP1 also
functions actively in cell adaptive responses to match O2
supply under hypoxia by supporting hypoxia-inducible
factor 1-alpha (HIF1α) at diﬀerent signaling levels. This
protein, together with PARP1, acts as a key modulator of the transcription response in cells that experience a low O2 level. Under normal oxygen condition, factor
inhibiting HIF1α (FIH1; asparaginyl hydroxylase) and propyl hydroxylase domain-containing enzymes (PHDs) hydroxylate HIF1α, thereby preventing transcription
factor interaction with EP300/CBP coactivators and marking HIF1α for proteasomal degradation by E3 ubiquitin ligase, the von Hippel-Lindau (pVHL) complex. Low
O2 concentration inhibits hydroxylases and stabilizes HIF1α. PARP1 forms complex and co-activates HIF1α in a PARP1 enzymatic activity-dependent manner,
therefore enabling expression of genes controlled by hypoxia response element (HRE)-positive promoters. This group comprises antioxidant defense enzymes such as
heme oxygenase-1 (HO-1), glutathione peroxidase 8 (GPX8), ER oxidoreductin 1 (ERO1) and glucose transporter 1 (GLUT1), the activity of which helps to maintain
glutathione homeostasis.
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Fig. 3. PARP1 contributes to regulation of
redox-related signaling pathways. PARP1
regulates both positively and negatively tran-
scription of numerous enzymes involved in the
transmitting signals to and from oxidant-re-
leasing intracellular systems or extracellular
sources. Expression of MAP2K6 and ERK1 are,
like PARP1, controlled by cell cycle progres-
sion and RB-based repressive complexes. In
proliferating cells, PARP1 is indispensable for
their transcription, because it mediates EP300
recruitment to their promoters. Although AKT
and ERK2 are not directly repressed by RBs,
PARP1 maintains their expression. All these
kinases were shown to protect proliferating
cells facing mild or physiological increases in
the electrophile abundance from death. In the
AKT pathway, PI3 acts as a redox sensor and
after activation phosphorylates AKT, which in
turn activates mTOR kinase. This enzyme sti-
mulates cell proliferation via the SGK1-FOXO3
pathway, which represses transcription of CDK
inhibitors. Moreover, mTOR phosphorylates
and inactivates BAD, thus blocking the release
of cytochrome c from mitochondria. AKT con-
tributes to H2O2 accumulation by stimulating
oxidative metabolism and FOXO-dependent repression of catalase. Growth factors and oxidants switch on ERK signaling via RAS, which, depending on the isoform
expressed in a particular cell type, shifts up or down the intracellular level of oxidants. Ha-RAS isoform promotes O2•- accumulation by activating NADPH oxidase,
while the Ki-RAS pathway upregulates transcription of SOD2. There are numerous ERK targets, which implicate this enzyme in cell proliferation: carbamoyl
phosphate synthetase (CPS II, source of pyrimidine nucleotides), MSK1/2 (chromatin remodeling and induction of cell cycle-related gene transcription), RNA
polymerase I (transcription of the ribosomal RNA genes), CDK inhibitors or MYC (transcription of cyclin D1). ERK protects cells from death by repressing pro-
apoptotic BIM and stabilizing anti-apoptotic MCL-1 protein. PARP1-MAP2K6 functional cross-talk at the genomic level is not limited to upregulation of kinase
transcription. MAP2K6 links PARP1 with transcription of anti-apoptotic genes indirectly by starting the phosphorylation cascade MAP2K6-p38-MSK1/2-CREB. The
last component of this axis controls transcription of HO-1 and PGC-1α; the latter promotes mitochondrial biogenesis. Furthermore, PARP1 regulates activity of
MAPKs independently of their promoters by regulating transcription of JNK, ER1/2 and the p38 inhibitor MKP1. Downregulation of MKP1 expression by PARP1
blocks dephosphorylation of tyrosine and threonine residues of MAPKs, which undergo activation upon acute cell exposure to H2O2.
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PARP1 level negatively correlates with mitochondrial SOD in cancer
cells (EMBL-EBI Expression Atlas), where SOD2 overexpression causes a
growth inhibitory eﬀect by shifting the O2•-/H2O2 balance towards
H2O2 accumulation [16]. If PARP1 is involved in SOD2 repression, this
enzyme could be capable of deﬁning the intracellular repertoire of
growth promoting or inhibiting oxidants. Furthermore, low SOD2 level
is known to stabilize HIF1α [17].
4. PARP1 regulates redox-sensitive signaling pathways
The roles that small species of oxidizing nature play in cellular
signaling are becoming increasingly appreciated. Redox-sensitive
pathways allow cells to adapt to mild oxidant/antioxidant imbalance
and promote survival by linking redox shifts to post-translational
modiﬁcations of proteins and to their interactome [5,18]. According to
our and previous ﬁndings, PARP1 regulates transcription of numerous
genes encoding redox sensors and mediators transmitting signals up-
stream or downstream of electrophile sources (Fig. 3). Redox-sensitive
MAP kinase signaling serves as a good example of the PARP1-MAPK-
ROS-cell survival axis since PARP1 couples transcription of MAP2K6,
ERK1/2 and AKT1 with the cell cycle progression, thereby assuring
active transcription of kinases that have a pro-survival function under
mild redox imbalance [19–26]. Furthermore, oxidative stress-induced
PARP1 activation represses transcription of MPK1, a known MAPK in-
hibitor [27]. Although in this particular case JNK and p38 were shown
to act as pro-death kinases, the beneﬁcial or detrimental activity of
kinases and MAPK pathways is determined by the type of intracellular
or extracellular stimuli that challenges redox homeostasis, for example
whether the action is acute or prolonged, mild or severe, but is also
dependent on the cell type. All these aspects also apply to PARP1. In
addition to conditions listed above, PARP1-dependent cell life or death
fate is determined by the pathway to which PARP1 contributes (pro-
survival or suicidal), the direction (inhibition or stimulation) and mode
of mutual interdependence with its interacting partner (direct protein-
protein binding or covalent modiﬁcation, i.e. ADP-ribosylation). Oxi-
dants are one of major agents triggering mono- or poly-ADP-ribosyla-
tion; the severity of oxidative stress determines the length of ADP
polymer synthesized, thus also impinging on the beneﬁcial or detri-
mental eﬀect of PARP1 activation, since NAD+ is utilized as a substrate
for ADP-ribosylation. High doses of H2O2 cause metabolic catastrophe,
parthanatos, and activation of detrimental signaling pathways, while
moderate PARylation protects cells from mild oxidative stress by at-
tracting DNA repair complexes, clearing and removal of oxidized or
damaged proteins, and re-establishing homeostasis [28,29].
5. Cell cycle determines DNA repair mechanisms
PARP1 actively contributes to numerous repair pathways of oxida-
tive DNA lesions, which comprise covalent modiﬁcations of nucleo-
bases as well as single and double strand breaks (SSB and DSB, re-
spectively). The deformability of DNA within SSB is recognized by two
ﬂexibly linked N-terminal zinc ﬁngers, and initiates self-assembly of
remaining PARP1 domains leading to activation of the C-terminal cat-
alytic domain [30]. In case of DSB induced by oxidative stress, JNK 6
phosphorylates SIRT6. This enzyme is rapidly mobilized to break sites,
where it potentiates recruitment and activation of PARP1, which in turn
stimulates DSB repair [31]. In proliferating cells all repair mechanisms
are active, and PARP1 is highly expressed to support SSB repair (SSBR),
base excision repair (BER), homologous recombination (HR), and al-
ternative non-homologous end joining (Alt-NHEJ), but inhibits classical
Fig. 4. PARP1 regulates repair of oxidative
DNA damages. The cell decision on involve-
ment of particular repair system depends on
the type of DNA damage and is strongly related
to cell cycle progression. For double strand
breaks, the cell is equipped with three repair
systems: homologous recombination (HR),
classical non-homologous end joining (C-
NHEJ) or alternative non-homologous end
joining (Alt-NHEJ). Proliferating cells, with
high PARP1 levels, make use mainly of two
mechanisms: HR and/or Alt-NHEJ, which as-
sure accurate and error-free repair of double
strand breaks since they use a replicated DNA
template to reconstruct the missing fragment
with high ﬁdelity. These two pathways rely on
the recognition of detrimental lesions by
PARP1, which recruits other proteins to the
aﬀected sites: ﬁrst MRN complex (consisting of
MRE11, Rad50, Nbs1), an initiator of repair,
then MRE11 determines the composition of
proteins for each repair mechanism (HR or
NHEJ). The low C-NHEJ involvement in repair
is achieved by high expression of PARP1, an
inhibitor of DNA-dependent protein kinases
(DNA-PKcs), which is crucial for C-NHEJ pro-
gression. In G1/G0 arrested cells (deﬁcient in
HR and Alt-NHEJ), low expression of PARP1
allows recruitment of the Ku70/80 hetero-
dimer to double strand breaks and sites of
DNA-PKcs activation. Repair machinery such as nuclease Artemis, DNA ligase IV and XRCC4 further process the damaged DNA and directly ligate DNA ends, leading
to the irreversible loss of genetic material. Base excision repair (BER) is a substantial pathway to repair oxidized bases. The damaged base is recognized and removed
by OGG1 glycosylase, which requires PARP1 for proper and eﬃcient functioning. AP endonuclease (APE1) is binds to apurynic sites and produces single-strand
breaks (SSBs), which again involve PARP1 in the BER machinery at a later repair step. DNA nick-induced poly-ADP-ribosylation facilitates PARP1 interaction with
DNAPδ/ε and PCNA, which further govern repair machinery. Single strand breaks resulting from direct oxidant action also need PARP1 activity to be repaired. Poly-
ADP-ribose polymers recruit XRCC1, then the remaining SSBR machinery comprising DNA polymerase (DNAP) and DNA ligase III, which also can be PARylated by
PARP1. PARP1 deﬁciency in growth-arrested cells substantially impairs both pathways. Of note, inhibition of OGG1 in combination with G1-blockade leads to further
accumulation of single strand breaks.
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non-homologous end joining (C-NHEJ) (Fig. 4). Thus PARP1 has be-
come a target for anticancer interventions. G1/G0 arrest shifts error-
free HR and Alt-NHEJ to error-prone C-NHEJ, but low PARP1 impairs
also BER and SSBR [32–34]. According to our new data, PARP1 re-
pression by CDK4/6 inhibitors reduces PARP1-dependent 8-oxoguanine
glycosylase (OGG1) activity, causing accumulation of single strand
breaks and thereby increasing cell vulnerability to anticancer drugs and
H2O2-induced oxidative stress [35]. The direct binding of OGG1 to
PARP1 is stimulated by increased oxidant level, and for full activity
OGG1 requires acetylation by EP300, which physically interacts with
PARP1 and is recruited to some genomic loci by PARP1 [36,37].
PARP1 has been postulated to cooperate with transcription factor(s)
that activate expression of genes encoding proteins contributing to DNA
repair [38]. Although such a premise must be experimentally con-
ﬁrmed, PARP1 is a bona ﬁde co-regulator of NF-κB, p53, AP-1, E2F1,
and BRCA1, which control promoter activation, epigenetic landscape
and miRNA transcription of DNA repairing machinery. The conﬁrma-
tion for likely contribution of PARP1 in regulation of DNA repair gene
transcription comes from observations in human growth arrested
monocytes diﬀerentiating to proliferating macrophages [39]. This
process was associated with increased PARP1 expression, but also with
transcriptional activation of XRCC1, ligase IIIα, OGG1 and catalytic
subunit of DNA-dependent protein kinase (DNA-PKcs). Severe DNA re-
pair defects that impacted base excision repair and double-strand break
repair in monocytes sensitized these cells to death by t-butyl hydro-
peroxide and irradiation with γ-rays, while macrophages revealed al-
most complete resistance to these redox-challenging agents.
To conclude, PARP1 provides cell with protection against oxidants
at diﬀerent levels: by activating expression of proteins setting up anti-
oxidant defense and redox sensitive signaling pathways, and by ﬁne
tuning of DNA repair machinery. Therefore PARP1 expression, which is
deﬁned by the proliferative status of cells, can determine cell resistance
to oxidants, even though an adaptive response is only apparent within a
narrow dose window.
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